OFEV® (nintedanib) time to face IPF head on IPF prevalence and diagnosis challenges Document ID: PC-ZA-101186 19/04/2021 Author: Boehringer Ingelheim Prof Ker: IPF prevalence and diagnosis challenges RELATED CONTENT PC-ZA-101186Production date: April 2021
